Yuan Dong Biotech (688513.SH): HP-002 tablets have initiated Phase I/II clinical trials and completed the first subject's enrollment and administration.

Zhitong Caijing APP News, Yuandong Biotechnology (688513.SH) announced that its holding subsidiary Shanghai Chaoyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Shanghai Chaoyang Pharmaceutical") has independently developed the class 1 innovative chemical drug HP002 tablets, which are currently undergoing phase I/II clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The first subject has recently been enrolled and dosed.